Sign Out
Fertility: Based on the mechanism of action, the use of NSAIDs, including Celecoxib, may delay or prevent rupture of ovarian follicles, which has been associated with reversible infertility in some women. In women who have difficulties conceiving or who are undergoing investigation of infertility, withdrawal of NSAIDs, including Celecoxib, should be considered.
Pregnancy: There are no studies in pregnant women. The relevance of these data for humans is unknown.
Celecoxib, as with other drugs inhibiting prostaglandin synthesis, may cause uterine inertia and premature closure of the ductus arteriosus and should be avoided during the third trimester of pregnancy. Celecoxib should be used during pregnancy only if the potential benefit to the mother justifies the potential risk to the fetus. Inhibition of prostaglandin synthesis might adversely affect pregnancy. If used during second or third trimester of pregnancy, NSAIDs may cause fetal renal dysfunction which may result in reduction of amniotic fluid volume or oligohydramnios in severe cases. Such effects may occur shortly after treatment initiation and are usually reversible. Pregnant women on Celecoxib should be closely monitored for amniotic fluid volume.
Lactation: Administration of Celecoxib to lactating women show very low transfer of Celecoxib into breast milk. Because of the potential for adverse reactions in nursing infants form Celecoxib, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the expected benefit of the drug to the mother.
